Combination of a factor Xa inhibitor and clopidogrel
US7018990B2 · kind B2 · utility
13Cited by
9References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2004 |
| Grant date | Mar 28, 2006 |
| Priority date | — |
| Expiry date | Sep 13, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application describes methods of using a combination of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-5-[[4-[(2′-dimethylaminomethyl)imidazol-1′-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt, a factor Xa inhibitor, and Clopidogrel as anticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.